GlassScriptPhysician profile
Ethan E Bickelhaupt
NPI 1760427389
$11,958.51
in general payments reported to CMS, 2019-2025
28 companies · $2,036 in 2025
The $2,036 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $220 · 2021: $870 · 2022: $3,005 · 2023: $3,283 · 2024: $2,167 · 2025: $2,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,386 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,385.70 |
| Education | $100.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,814.98 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,627.11 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,015.91 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $925.51 | 2021-2025 | Caplyta |
| Alkermes, INC. | $898.86 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Tris Pharma INC | $886.52 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Sunovion Pharmaceuticals INC. | $706.05 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $634.46 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $583.43 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $457.55 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $353.69 | 2022-2024 | Auvelity |
| Lundbeck LLC | $341.71 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $331.57 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $286.97 | 2022-2024 | Spravato, Invega, Invega Trinza |
| Bausch Health US, LLC | $218.14 | 2021-2025 | Aplenzin, Wellbutrin |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $214.37 | 2021-2023 | Adzenys Xr-Odt |
| Corium, LLC | $206.53 | 2021-2023 | Azstarys |
| Almatica Pharma LLC | $102.00 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $74.17 | 2023-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $53.81 | 2022-2023 | Jornay Pm |
| Eisai INC. | $51.89 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.30 | 2022 | |
| Jazz Pharmaceuticals INC. | $40.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.97 | 2023 | Quviviq |
| Biogen, INC. | $19.58 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.61 | 2022 | |
| Acadia Pharmaceuticals INC | $15.51 | 2023 | Nuplazid |
| Sumitomo Pharma America, INC. | $15.28 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Bickelhaupt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.